ArticleFuture oncology (London, England)2025
Immunotherapy and combination treatments for triple-negative breast cancer: a Scopus bibliometric perspective.
Article in Future oncology (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Global scientific growth and thematic development of spatial transcriptomics in oncology research.Discover oncology · 2026Article
- Unraveling Research Trends and Hotspots of Genetic Variants in Acute Leukemias: A Web of Science and Scopus-Based Bibliometric Study.International journal of medical sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundImmunotherapy, a cornerstone treatment for triple-negative breast cancer (TNBC), has several limitations as a monotherapy. Global research is actively investigating effective combinatorial immunotherapy treatments for TNBC. Aim: This study aimed to elucidate an overview and research hot spots of immunotherapy and its combinatorial regimens in TNBC management for the past 5 years. MATERIALS &
methodsPublications were retrieved from Scopus from 2019 to 2023 and analyzed using Harzing's Publish or Perish, Microsoft Excel, and VOSviewer.
resultsThe study included a total of 1,818 publications, demonstrating increased publication trends over the years. The most productive continent, country, and journal were Asia (TP = 957), the United States (TP = 653), and Cancers (TP = 123), respectively. The United States and China exhibited the most dynamic inter-country collaboration, evidenced by the highest link strength (69). The United States emerged as the most influential country, recording the highest TLS (520). The analysis of co-occurrence author keywords revealed ICIs, PD-L1, and TME as research hot spots. The thorough integration of knowledge and research on these hot spots may offer an alternative in the management of TNBC.
conclusionIt is imperative to identify combinatorial immunotherapy treatments in order to have better cancer management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.